Overview In line with grant requirements, the C-SiG Pilot and Feasibility (P/F) Program: 1) Supports both new investigators just beginning their careers in digestive diseases research or innovative research proposals from experienced investigators who plan to change their area of research;ii) Provides investigators with vital funds to obtain preliminary data that support research grant applications from external agencies, especially NIH ROl grant submissions;and, iii) Provides mentorship, critical review of proposals, and coaching to improve the competitiveness of grant applications. We are strongly focused on junior investigators and Mayo Clinic has a sustained and rich tradition of facilitating the transition of junior investigators to independent scientists. As of February 2013, there were 1932 fellows (1311 MD (or equivalent), 130 MD/PhD, and 491 PhD) and 113 research trainees at Mayo Clinic Rochester. The Division of Gastroenterology and Hepatology (GIH) had a total of 82 fellows (36 fellows in the clinical training program, 5 fellows on our longstanding NIH Gl training grant, 41 postdoctoral research fellows) and 15 research trainees. GIH junior investigators comprise 26% of P/F applicants and 46% of the awardees. The C-SiG P/F Program works closely with the GIH Division and other Departments and Centers to help junior investigators achieve independent funding and to bring experienced investigators with C-SiG-relevant expertise into digestive disease research.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
2P30DK084567-06
Application #
8737740
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ni, Jun; Wangensteen, Kirk J; Nelsen, David et al. (2016) Active recombinant Tol2 transposase for gene transfer and gene discovery applications. Mob DNA 7:6
Landry, Greg M; Hirata, Taku; Anderson, Jacob B et al. (2016) Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol 310:F152-9
Ma, Alvin C; McNulty, Melissa S; Poshusta, Tanya L et al. (2016) FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science. Hum Gene Ther 27:451-63
Khanna, S; Montassier, E; Schmidt, B et al. (2016) Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:715-27
Druliner, Brooke R; Rashtak, Shahrooz; Ruan, Xiaoyang et al. (2016) Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation. Transl Oncol 9:280-6
Tomita, Kyoko; Freeman, Brittany L; Bronk, Steven F et al. (2016) CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 6:28786
Kawakami, Hisato; Huang, Shengbing; Pal, Krishnendu et al. (2016) Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 15:3015-3027
Tabibian, James H; Varghese, Cyril; LaRusso, Nicholas F et al. (2016) The enteric microbiome in hepatobiliary health and disease. Liver Int 36:480-7
Verma, Vikas K; Li, Haiyang; Wang, Ruisi et al. (2016) Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol 64:651-60
Ding, Xiwei; Chaiteerakij, Roongruedee; Moser, Catherine D et al. (2016) Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 7:20080-92

Showing the most recent 10 out of 399 publications